Steven Plaxe

Title(s)Professor Of Clinical, Ob/Gyn & Reproductive sciences
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Overview 
    Collapse Websites

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Practice patterns and survival in FIGO 2009 stage 3B endometrial cancer. Gynecol Oncol. 2021 Sep 21. Jou J, Charo L, Hom-Tedla M, Coakley K, Binder P, Saenz C, Eskander RN, McHale M, Plaxe S. PMID: 34561099.
      View in: PubMed   Mentions:    Fields:    
    2. Positron Emission Tomography-Guided Bone Marrow-Sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: Final Results From the INTERTECC Phase II/III Trial. Int J Radiat Oncol Biol Phys. 2021 Aug 20. Williamson CW, Sirák I, Xu R, Portelance L, Wei L, Tarnawski R, Mahantshetty U, Heide ES, Yashar CM, McHale MT, Bosch W, Lowenstein J, Saenz CC, Plaxe S, Eskander R, Einck J, Mundt AJ, Mayadev J, Mell LK. PMID: 34419564.
      View in: PubMed   Mentions:    Fields:    
    3. Trends and geographic variation in women's representation as principal investigators (PI) in phase 3 gynecologic oncology clinical trials. Gynecol Oncol. 2021 Aug; 162(2):389-393. Jou J, Brodsky A, Charo L, Binder P, Saenz C, Eskander RN, McHale M, Plaxe S. PMID: 34099315.
      View in: PubMed   Mentions:    Fields:    
    4. Advanced uterine papillary serous cancer: Could there be a role for newer targeted therapeutic approaches or immune checkpoint inhibitors? J Oncol Pharm Pract. 2021 Jul; 27(5):1181-1185. Dasanu CA, Lerner J, Ocampo MM, Iskandar AS, Kaur J, Tuler S, Codreanu I, Farrell S, Plaxe SC. PMID: 33983075.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery. Oncologist. 2021 04; 26(4):e530-e536. Kato S, McFall T, Takahashi K, Bamel K, Ikeda S, Eskander RN, Plaxe S, Parker B, Stites E, Kurzrock R. PMID: 33528846.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Assessment of malnutrition by unintentional weight loss and its implications on oncologic outcomes in patient with locally advanced cervical cancer receiving primary chemoradiation. Gynecol Oncol. 2021 03; 160(3):721-728. Jou J, Coulter E, Roberts T, Binder P, Saenz C, McHale M, Plaxe S, Mayadev J, Eskander RN. PMID: 33342621.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    7. HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease. Gynecol Oncol. 2021 04; 161(1):25-33. Jou J, Zimmer Z, Charo L, Yau C, Saenz C, Eskander R, McHale M, Veerapong J, Plaxe S, Binder P. PMID: 33293046.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. Charting a professional course for academic gynecologic oncology mentors. Gynecol Oncol. 2021 01; 160(1):265-270. Jou J, Binder P, Saenz C, Eskander R, McHale M, Plaxe S. PMID: 33131903.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020 10 02; 11(1):4965. Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, Kuo DJ, Eskander RN, Goodman A, Galanina N, Fanta PT, Schwab RB, Shatsky R, Plaxe SC, Sharabi A, Stites E, Adashek JJ, Okamura R, Lee S, Lippman SM, Sicklick JK, Kurzrock R. PMID: 33009371.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    10. Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States. Gynecol Oncol. 2020 12; 159(3):681-686. Charo LM, Jou J, Binder P, Hohmann SF, Saenz C, McHale M, Eskander RN, Plaxe S. PMID: 32977989.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    11. Phase 1 Trial of Concurrent Gemcitabine and Cisplatin with Image Guided Intensity Modulated Radiation Therapy for Locoregionally Advanced Cervical Carcinoma. Int J Radiat Oncol Biol Phys. 2020 08 01; 107(5):964-973. Mell LK, Xu R, Yashar CM, McHale MT, Einck JP, Mayadev J, Lee E, Binder P, Rash D, Eskander R, Heide ES, Plaxe SC, Mundt AJ, Saenz CC. PMID: 32334034.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    12. Rapid dissemination of practice-changing information: A longitudinal analysis of real-world rates of minimally invasive radical hysterectomy before and after presentation of the LACC trial. Gynecol Oncol. 2020 05; 157(2):494-499. Charo LM, Vaida F, Eskander RN, Binder P, Saenz C, McHale M, Plaxe S. PMID: 32081462.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. The elevated risk of ovarian clear cell carcinoma among Asian Pacific Islander women in the United States is not affected by birthplace. Gynecol Oncol. 2020 04; 157(1):62-66. Korenaga TR, Ward KK, Saenz C, McHale MT, Plaxe S. PMID: 32008796.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019. F1000Res. 2019; 8. Charo LM, Plaxe SC. PMID: 31231511.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    15. Merkel cell carcinoma: long-term follow-up of a single institution series and clinical outcomes by immunological status. Dermatol Online J. 2019 02 15; 25(2). Dasanu CA, Del Rosario M, Codreanu I, Lu Y, Farrell S, Hyams DM, Plaxe SC. PMID: 30865403.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. Survival of women with microinvasive adenocarcinoma of the cervix is not improved by radical surgery. Am J Obstet Gynecol. 2017 09; 217(3):332.e1-332.e6. Bean LM, Ward KK, Plaxe SC, McHale MT. PMID: 28522318.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    17. Fertility preservation and survival among young women with early ovarian cancer living in US counties with gynecologic oncologist services. Int J Gynaecol Obstet. 2017 May; 137(2):157-163. Hillman RT, Saenz CC, McHale MT, Plaxe SC. PMID: 28170079.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Longitudinal Changes in Active Bone Marrow for Cervical Cancer Patients Treated With Concurrent Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2017 03 15; 97(4):797-805. Noticewala SS, Li N, Williamson CW, Hoh CK, Shen H, McHale MT, Saenz CC, Einck J, Plaxe S, Vaida F, Yashar CM, Mell LK. PMID: 28244416.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    19. Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2). Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):536-545. Mell LK, Sirák I, Wei L, Tarnawski R, Mahantshetty U, Yashar CM, McHale MT, Xu R, Honerkamp-Smith G, Carmona R, Wright M, Williamson CW, Kasaová L, Li N, Kry S, Michalski J, Bosch W, Straube W, Schwarz J, Lowenstein J, Jiang SB, Saenz CC, Plaxe S, Einck J, Khorprasert C, Koonings P, Harrison T, Shi M, Mundt AJ, INTERTECC Study Group . PMID: 28126303.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    20. Industry Payments to Obstetrician-Gynecologists: An Analysis of 2014 Open Payments Data. Obstet Gynecol. 2016 Feb; 127(2):376-82. Tierney NM, Saenz C, McHale M, Ward K, Plaxe S. PMID: 26942368.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    21. Urinary diversions: A time to enrich surgical training? Gynecol Oncol. 2016 Jan; 140(1):120-3. Shah NR, Ward KK, Plaxe SC, Saenz CC, McHale MT. PMID: 26556767.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    22. Increased prevalence of comorbid conditions in women with uterine cancer. Gynecol Oncol. 2015 Sep; 138(3):731-4. Kurnit KC, Ward KK, McHale MT, Saenz CC, Plaxe SC. PMID: 26160712.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    23. Combinatorial influences of paclitaxel and strain on axonal transport. Exp Neurol. 2015 Sep; 271:358-67. Bober BG, Gutierrez E, Plaxe S, Groisman A, Shah SB. PMID: 26143110.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    24. Barriers prevent patient access to personalized therapies identified by molecular tumor profiling of gynecologic malignancies. J Pers Med. 2015 May 21; 5(2):165-73. Hillman RT, Ward K, Saenz C, McHale M, Plaxe S. PMID: 26011384.
      View in: PubMed   Mentions:
    25. Clinical Outcomes of Computed Tomography-Based Volumetric Brachytherapy Planning for Cervical Cancer. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):150-7. Simpson DR, Scanderbeg DJ, Carmona R, McMurtrie RM, Einck J, Mell LK, McHale MT, Saenz CC, Plaxe SC, Harrison T, Mundt AJ, Yashar CM. PMID: 26130230.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    26. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer. 2014 Nov; 24(9):1583-9. Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, Morris RT, Akerley WL, Holloway RW, Method MW, Plaxe SC, Walker JL, Friccius-Quecke H, Krasner CN. PMID: 25254563.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    27. Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials. J Natl Cancer Inst. 2014 Jul; 106(7). Donovan KA, Donovan HS, Cella D, Gaines ME, Penson RT, Plaxe SC, von Gruenigen VE, Bruner DW, Reeve BB, Wenzel L. PMID: 25006190.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    28. Bariatric surgery decreases the risk of uterine malignancy. Gynecol Oncol. 2014 Apr; 133(1):63-6. Ward KK, Roncancio AM, Shah NR, Davis MA, Saenz CC, McHale MT, Plaxe SC. PMID: 24680593.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    29. The risk of uterine malignancy is linearly associated with body mass index in a cohort of US women. Am J Obstet Gynecol. 2013 Dec; 209(6):579.e1-5. Ward KK, Roncancio AM, Shah NR, Davis MA, Saenz CC, McHale MT, Plaxe SC. PMID: 23938608.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    30. Excess risk of Clostridium difficile infection in ovarian cancer is related to exposure to broad-spectrum antibiotics. Support Care Cancer. 2013 Nov; 21(11):3103-7. Kim JS, Ward KK, Shah NR, Saenz CC, McHale MT, Plaxe SC. PMID: 23839499.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    31. Use of psychosocial services increases after a social worker-mediated intervention in gynecology oncology patients. Health Soc Work. 2013 May; 38(2):113-21. Abbott Y, Shah NR, Ward KK, McHale MT, Alvarez EA, Saenz CC, Plaxe SC. PMID: 23865288.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    32. Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. Clin Exp Metastasis. 2013 Jun; 30(5):579-94. Ward KK, Tancioni I, Lawson C, Miller NL, Jean C, Chen XL, Uryu S, Kim J, Tarin D, Stupack DG, Plaxe SC, Schlaepfer DD. PMID: 23275034.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    33. Women with gynecologic malignancies have a greater incidence of suicide than women with other cancer types. Suicide Life Threat Behav. 2013 Feb; 43(1):109-15. Ward KK, Roncancio AM, Plaxe SC. PMID: 23278597.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    34. Changing demographics of cervical cancer in the United States (1973-2008). Gynecol Oncol. 2012 Sep; 126(3):330-3. Ward KK, Shah NR, Saenz CC, McHale MT, Alvarez EA, Plaxe SC. PMID: 22668881.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    35. Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol Oncol. 2012 Aug; 126(2):176-9. Ward KK, Shah NR, Saenz CC, McHale MT, Alvarez EA, Plaxe SC. PMID: 22507532.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    36. Primary squamous carcinoma of the ovary likely arising from a monodermal cystic mucinous teratoma. Ann Diagn Pathol. 2011 Dec; 15(6):446-9. Baughn MR, Plaxe SC, Weidner N. PMID: 20952274.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    37. Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studies. Am J Obstet Gynecol. 2008 Nov; 199(5):539.e1-6. Plaxe SC, Brooks SE, Tian C, Bloss JD, Moore DH, Long HJ. PMID: 18565487.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    38. Epidemiology of low-grade serous ovarian cancer. Am J Obstet Gynecol. 2008 Apr; 198(4):459.e1-8; discussion 459.e8-9. Plaxe SC. PMID: 18395040.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    39. A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Cancer Chemother Pharmacol. 2002 Aug; 50(2):151-4. Plaxe SC, Blessing JA, Olt G, Husseinzadah N, Lentz SS, DeGeest K, Valea FA. PMID: 12172981.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    40. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2002 Feb; 84(2):241-4. Plaxe SC, Blessing JA, Husseinzadeh N, Webster KD, Rader JS, Dunton CJ. PMID: 11812081.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    41. Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study. Am J Clin Oncol. 2002 Feb; 25(1):45-7. Plaxe SC, Blessing JA, Morgan MA, Carlson J, Gynecologic Oncology Group . PMID: 11823695.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    42. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2002 Jan; 84(1):32-5. Plaxe SC, Blessing JA, Bookman MA, Creasman WT. PMID: 11748972.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    43. A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix--a Gynecologic Oncology Group Study. Invest New Drugs. 2001; 19(1):77-80. Plaxe SC, Blessing JA, Lucci JA, Hurteau JA. PMID: 11291835.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    44. Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel. Cancer Chemother Pharmacol. 2000; 45(5):381-8. de las Alas MM, Christen RD, Gately DP, Weiner DE, Benbatoul K, Kirmani S, D'Agostino HR, Plaxe SC, Darrah D, McClay EF, Aebi S, Howell SB, Los G. PMID: 10803921.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    45. Estimation of the duration of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening. Gynecol Oncol. 1999 Oct; 75(1):55-61. Plaxe SC, Saltzstein SL. PMID: 10502426.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    46. Transcervical metallic stents for drainage of uterine collections. J Vasc Interv Radiol. 1999 May; 10(5):629-33. Gooding JM, D'Agostino HB, Plaxe SC. PMID: 10357490.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    47. Field cancerization: why late "recurrent" ovarian cancer is not recurrent. Am J Obstet Gynecol. 1998 Apr; 178(4):641-9. Buller RE, Skilling JS, Sood AK, Plaxe S, Baergen RN, Lager DJ. PMID: 9579425.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    48. Phase I and pharmacokinetic study of intraperitoneal topotecan. Invest New Drugs. 1998; 16(2):147-53. Plaxe SC, Christen RD, O'Quigley J, Braly PS, Freddo JL, McClay E, Heath D, Howell SB. PMID: 9848578.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    49. Impact of ethnicity on the incidence of high-risk endometrial carcinoma. Gynecol Oncol. 1997 Apr; 65(1):8-12. Plaxe SC, Saltzstein SL. PMID: 9103384.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    50. Phase I trial of cisplatin in combination with glutathione. Gynecol Oncol. 1994 Oct; 55(1):82-6. Plaxe S, Freddo J, Kim S, Kirmani S, McClay E, Christen R, Braly P, Howell S. PMID: 7959273.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    51. Ovarian cancer. Med Sect Proc. 1994; 121-8. Plaxe SC. PMID: 7659707.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    52. Phase I and pharmacokinetic study of intraperitoneal ormaplatin. Gynecol Oncol. 1993 Oct; 51(1):72-7. Plaxe SC, Braly PS, Freddo JL, McClay E, Christen RD, Kirmani S, Kim S, Heath D, Howell SB. PMID: 8244179.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    53. Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer. Obstet Gynecol. 1993 May; 81(5 ( Pt 1)):651-4. Plaxe SC, Braly PS, Freddo JL, McClay E, Kirmani S, Howell SB. PMID: 8469449.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    54. A simplified approach to superficial inguinal dissection with sparing of the saphenous vein in patients with carcinoma of the vulva. Surg Gynecol Obstet. 1993 Mar; 176(3):295-6. Plaxe SC, Braly PS, Dottino PR. PMID: 8438204.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    55. Clinical features and treatment outcome of patients with epithelial carcinoma of the ovary metastatic to the central nervous system. Obstet Gynecol. 1990 Feb; 75(2):278-81. Plaxe SC, Dottino PR, Lipsztein R, Dalton J, Cohen CJ. PMID: 2300357.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    Steven's Networks
    Concepts (262)
    Derived automatically from this person's publications.
    _
    Co-Authors (39)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _